Laurence Delbos

Laurence Delbos

Auto-generated profile, based on publicly available information

Laurence Delbos

Nantes Université, CHU Nantes, INSERM, Center for Research in Transplantation and Translational Immunology, UMR 1064, ITUN2, F-44000, Nantes, France

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 July 2021 in The Journal of Immunology
Verified
Journal Article
Closed access
PDF file
MLMelanie Lancien
Melanie Lancien
GBGeraldine Bienvenu
Geraldine Bienvenu
SSSonia Salle
Sonia Salle
LGLucile Gueno
Lucile Gueno
MFMagalie Feyeux
Magalie Feyeux
CLCedric Louvet
Cedric Louvet
Intracellular ion fluxes emerge as critical actors of immunoregulation but still remain poorly explored. In this study, we investigated the role of the redundant cation channels TMEM176A and TMEM176B (TMEM176A/B) in retinoic acid–related orphan receptor γt+ cells and conventional dendritic cells (DCs) using germline and conditional double knockout mice. Although Tmem176a/b appeared surprisingly dispensable for the protective function of Th17 and group 3 innate lymphoid cells in the intestinal mucosa, we found that they were required in conventional DCs for optimal Ag processing and presentation to CD4+ T cells. Using a real-time imaging method, we show that TMEM176A/B accumulate in dynamic post-Golgi vesicles preferentially linked to the late endolysosomal system and strongly colocalize with HLA-DM. Taken together, our results suggest that TMEM176A/B ion channels play a direct role in the MHC class II compartment of DCs for the fine regulation of Ag presentation and naive CD4+ T cell priming. Key Points Germline and conditional double KO mice target Tmem176a and Tmem176b. Tmem176a/b appear dispensable in RORγt+ cells. Tmem176a/b are required in DCs for optimal MHC class II–mediated antigen presentation.

28 July 2023 in Blood Advances
Verified
Journal Article
Open access
PDF file
CBCecile Braudeau
Cecile Braudeau
LDLaurence Delbos
Laurence Delbos
MCMarie-Laure Couec
Marie-Laure Couec
GDGwenvael Danic
Gwenvael Danic
JCJustine Chevreuil
Justine Chevreuil
JMJérôme Martin
Jérôme Martin
Cecile Braudeau, Laurence Delbos, Marie-Laure Couec, Gwenvael Danic, Justine Chevreuil, Camille Lecuroux, Audrey Grain, Marion Eveillard, Fanny Rialland-Battist

7 November 2024 in European Journal of Immunology
Verified
Journal Article
Open access
FBFrançois Brinas
François Brinas
NSNicolas Sailliet
Nicolas Sailliet
GTGaëlle Tilly
Gaëlle Tilly
LDLaurence Delbos
Laurence Delbos
CKClarisse Kerleau
Clarisse Kerleau
RDRichard Danger
Richard Danger
The use of immunosuppressive treatment is required to prevent rejection events, even a long time after kidney transplantation despite rare recipients achieving long‐term graft stability without the need for immunosuppressive treatment, called operationally tolerant patients (TOLs). We comprehensively investigate the immune system of long‐term IS recipients (LTTs) and TOLs to highlight their shared and unique immune features. Blood immune cell phenotyping was performed by spectral cytometry. Samples from 34 individuals were analyzed, including 6 LTTs, 8 TOLs, 10 stable patients at 1 year posttransplantation (STAs), and 10 healthy volunteers. B cells differed between LTTs and TOLs with a decreased total B‐cell frequency and the acquisition of a memory phenotype in LTTs whereas a naive phenotype is maintained in TOLs. The frequencies of IgD−CD27− B cells and CD11c+ memory B cells are increased in LTTs, with an exhausted phenotype, evoked by a significant decrease in CD25 expression. These CD11c+ B cells display an exhausted phenotype similar to those found in several chronic immune diseases in which they have been shown to participate in their pathophysiology, suggesting active chronic inflammation in LTTs. Altogether, these data indicate that precautions should be taken to minimize IS use.

9 April 2021 in bioRxiv
Verified
Preprint
Open access
PDF file
AFAurélie Fantou
Aurélie Fantou
ELEric Lagrue
Eric Lagrue
TLThomas Laurent
Thomas Laurent
LDLaurence Delbos
Laurence Delbos
SBStéphanie Blandin
Stéphanie Blandin
AAAhmed Abidi
Ahmed Abidi
Crohn’s disease (CD), a form of inflammatory bowel disease (IBD), is characterized by impaired epithelial barrier functions and dysregulated mucosal immune responses. IL-22 binding protein (IL-22BP) is a soluble inhibitor regulating IL-22 bioactivity, a cytokine proposed to play protective roles during CD. We and others have shown that IL-22BP is produced in IBD inflamed tissues, hence suggesting a role in CD. In this work, we extended the characterization of IL-22BP production and distribution in CD tissues by applying enzyme-linked immunosorbent assays to supernatants obtained from the culture of endoscopic biopsies of patients, and reverse transcription-quantitative polymerase chain reaction on sorted immune cell subsets. We reveal that IL-22BP levels are higher in inflamed ileums than colons. We observe that in a cell-intrinsic fashion, populations of mononuclear phagocytes and eosinophils express IL-22BP at the highest levels in comparison to other sources of T cells. We suggest the enrichment of intestinal eosinophils could explain higher IL-22BP levels in the ileum. In inflamed colon, we reveal the presence of increased IL-22/IL22BP ratios compared to controls, and a strong correlation between IL-22BP and CCL24. We identify monocyte-derived dendritic cells (moDC) as a cellular subtype co-expressing both cytokines and validate our finding using in vitro culture systems. We also show that retinoic acid induces the secretion of both IL-22BP and CCL24 by moDC. Finally, we report on higher IL-22BP levels in active smokers. In conclusion, our work provides new information relevant to therapeutic strategies modulating IL-22 bioactivity in CD, especially in the context of disease location.

9 February 2026 in medRxiv
Verified
Preprint
Open access
PDF file
SMS. Marchand
S. Marchand
ATA. Trochel
A. Trochel
MLM. Loirat
M. Loirat
JMJ. Mignon
J. Mignon
TLThibault Letellier
Thibault Letellier
DMDorian McILROY
Dorian McILROY
BK polyomavirus (BKPyV) is a major complication in kidney transplant recipients (KTR), for whom no specific antiviral therapy is available. Modulation of immunosuppressive therapy results in virus clearance in most KTR with BKPyV DNAemia (controllers), but a significant minority fail to clear the virus (non-controllers). Here, we adapt LIBRA-seq, which links antibody sequence data to antigen specificity, to intact viral capsids of the four BKPyV genotypes to study and compare BKPyV-specific B-cell repertoires in controllers (n=8) versus non-controllers (n=3). Sequences were obtained for 5197 BKPyV-specific antibodies, and predicted antigen specificities were validated by ELISA and neutralizing assays (n=21 antibodies). We show that cross-genotype reactivity results from the recruitment of numerous broadly cross-reactive B-cell clones with preferential binding to the infecting genotype, making up 4,3% to 44,6% of the BKPyV-specific repertoire, while true broadly neutralizing antibodies are rare. The proportions of broadly-specific and isotype switched antibodies, rates of somatic hypermutation and repertoire diversity were comparable in both patient groups, indicating that there is no identifiable deficit in the humoral response mounted by BKPyV non-controllers, and supporting the notion that humoral immunity alone is insufficient to control established BKPyV replication. This work shows that LIBRA-seq can be successfully applied to a non-enveloped virus and provides a framework for analyzing antiviral B-cell repertoires and antibody specificity in clinically relevant settings. Abstract Figure:

1 April 2009 in Journal of Hepatology
Verified
Journal Article
Closed access
SNS. Naveau
S. Naveau
NBN. Barriova
N. Barriova
LBL. Bouchet-Delbos
L. Bouchet-Delbos
MNM. Njiké-Nakseu
M. Njiké-Nakseu
ABA. Balian
A. Balian
GPG. Perlemuter
G. Perlemuter